Resources to help your patients manage out-of-pocket expenses for LENVIMA®, including information about the Eisai Assistance Program and the LENVIMA® Patient Assistance Program.
The Eisai Assistance Program is your resource for information about your patients’ benefits for LENVIMA® and available financial assistance options. Our specialists will complete a full benefit investigation to understand your patients’ insurance coverage for LENVIMA®. If needed, our specialists can also discuss options for financial assistance to help your patients access LENVIMA®.
The LENVIMA® $0 Co-pay Program offers commercially insured patients a $0 co-pay on each prescription, with a $40,000 annual limit. Please call the Eisai Assistance Program at 1-866-61-EISAI (1-866-613-4724) for more information.
*Maximum benefit: The LENVIMA® $0 Co-pay Program provides up to $40,000 per year to assist with the out-of-pocket costs for LENVIMA®. Depending on the insurance plan, your patient could have additional financial responsibility for any amounts over Eisai’s maximum liability.
Eligibility criteria: Good toward the purchase of LENVIMA® prescriptions. No substitutions permitted. Not available to patients eligible for state or federal healthcare programs, including Medicare, Medicaid, Medigap, VA, DoD, or TRICARE. Offer only available to patients with private, commercial insurance. Offer available to MA residents through June 30, 2019. May not be combined with any other coupon, discount, prescription savings card, free trial, or other offer. Void outside the USA and where prohibited by law. Eisai Inc. reserves the right to rescind, revoke, or amend this offer at any time without notice. Patients, physicians and pharmacies are responsible for disclosing to insurance carriers the redemption and value of the program and complying with any other conditions imposed by insurance carriers on third-party payors. The value of this program is not contingent on any prior or future purchases. This program is solely intended to provide savings on a purchase of LENVIMA®. Use of this program for any one purchase does not obligate the patient to make future purchases of LENVIMA® or any other product. This offer will expire March 31, 2020.
Eisai has established the Patient Assistance Program for patients who need help paying for LENVIMA®. This program provides LENVIMA® at no cost to uninsured and financially burdened patients who meet the program eligibility criteria.
Eisai cannot guarantee payment of any claim. Coding, coverage, and reimbursement may vary significantly by payor, plan, patient, and setting of care. Actual coverage and reimbursement decisions are made by individual payors following the receipt of claims. For additional information, customers should consult with their payors for all relevant coding, reimbursement, and coverage requirements. It is the sole responsibility of the provider to select the proper code and ensure the accuracy of all claims used in seeking reimbursement. All services must be medically appropriate and properly supported in the patient medical record.
LENVIMA is indicated:
Permanently discontinue following an arterial thrombotic event. The safety of resuming after an arterial thromboembolic event has not been established and LENVIMA has not been studied in patients who have had an arterial thromboembolic event within the previous 6 months.
Promptly initiate management of diarrhea. Withhold and resume at reduced dose upon recovery or permanently discontinue based on severity.
For more information about LENVIMA, please see available full Prescribing Information.
This information is intended for use by our healthcare professionals in the United States only. Eisai Inc. recognizes the Internet is a global communications medium; however, laws, regulatory requirements and medical practices for pharmaceutical products vary from country to country. The Prescribing Information included here is not appropriate for use outside the United States. This site contains information about products that may have different product labeling in different countries. This site is published by Eisai Inc.
LENVIMA® is a registered trademark used by Eisai under license from Eisai R & D Management Co., Ltd.